Olezarsen not checked
Ionis Pharmaceuticals, Inc. · ISIS 678354
FollowEvery change as it happens, and a Monday email
Trials
4 active
11 in total · 6 in the EU
What this is
- How it works
- A short strand of genetic material that blocks one gene's message, so the body makes less of one protein.APOC-III-directed RNA Interaction; Antisense Oligonucleotide FDA class
- Tested for
- Familial Chylomicronemia Syndrome (3 trials), Severe Hypertriglyceridemia
- Main trialPhase 3
- “The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.”In the company’s words, NCT05681351 on ClinicalTrials.gov
- Other names
- ISIS 678354 · AKCEA-APOCIII-LRx · IONIS-APOCIII-LRx
Other drugs for Familial Chylomicronemia Syndrome
- RN0361Ikaria Bioscience · Phase 1/2
Coming up4
- Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- Aug 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Mar 2027 | CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | |
| Phase 3Active, not recruiting | Jun 2027 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen | |
| Phase 3Active, not recruiting | Feb 2028 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) | |
| Phase 3Recruiting | Aug 2030 | A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants | |
| Phase 3Completed | 14 Jul 2023 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) | |
| Phase 3Completed | 8 Aug 2024 | A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia | |
| Phase 3Completed | 22 Oct 2024 | A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia | |
| Phase 3Completed | 17 Dec 2024 | A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia | |
| Phase 2Completed | 25 Nov 2019 | Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) | |
| Phase 2Completed | 22 Mar 2023 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia | |
| Phase 1Completed | 22 May 2023 | A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026